Luminex Corporation Company Profile (NASDAQ:LMNX)

Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."

Luminex Corporation declared a quarterly dividend on Thursday, May 25th. Shareholders of record on Friday, June 23rd will be given a dividend of $0.06 per share on Friday, July 14th. This represents a $0.24 annualized dividend and a yield of 1.13%. The ex-dividend date is Wednesday, June 21st. View Luminex Corporation's Dividend History.

Luminex Corporation (NASDAQ:LMNX) released its quarterly earnings data on Monday, May, 1st. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.12. The business earned $77.80 million during the quarter, compared to analyst estimates of $74.25 million. Luminex Corporation had a return on equity of 5.48% and a net margin of 5.00%. The business's revenue was up 23.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.29 earnings per share. View Luminex Corporation's Earnings History.

6 brokers have issued 1-year price targets for Luminex Corporation's stock. Their predictions range from $18.00 to $27.00. On average, they anticipate Luminex Corporation's stock price to reach $21.40 in the next year. View Analyst Ratings for Luminex Corporation.

Here are some recent quotes from research analysts about Luminex Corporation stock:

• 1. According to Zacks Investment Research, "Over the past one year, Luminex outperformed the broader industry in terms of price performance. The company operates in a highly competitive life sciences industry, which is likely to mar its growth trajectory in the coming quarters. Reduced spending on research and diagnostics by Luminex’ partner companies are adversely impacting the demand for the company’s products of late. Luminex may be impacted by future changes to the reimbursement landscape in the molecular diagnostic market. Luminex reported stable first-quarter 2017 results, beating the Zacks Consensus Estimates on both lines. Onthe positive side, the company’s Assay business will be its key growth driver over the long term. We are also optimistic about the company’s products – ARIES and NxTAG RPP – which represent a major revenue opportunity." (5/4/2017)
• 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Some companies that are related to Luminex Corporation include Accelerate Diagnostics (AXDX), ABAXIS (ABAX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL), Mazor Robotics (MZOR), GenMark Diagnostics (GNMK), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Viveve Medical (VIVE), Alliance HealthCare Services (AIQ), FULGENT GENETIC (FLGT), Cytosorbents Corporation (CTSO), Neovasc (NVCN), IRIDEX Corporation (IRIX) and Cogentix Medical (CGNT).

Luminex Corporation's management team includes the folowing people:

• G. Walter Loewenbaum II, Independent Chairman of the Board
• Nachum Shamir, President, Chief Executive Officer, Director
• Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer
• Richard W. Rew II, Senior Vice President, General Counsel, Secretary
• Nancy M. Fairchild, Senior Vice President - Human resources
• Randall Myers, Senior Vice President - Global Manufacturing and Quality
• Robert J. Cresci, Independent Director
• Stephen L Eck, Independent Director
• Thomas Willard Erickson, Independent Director
• Jimmy Dale Kever, Independent Director

Luminex Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.36%), VILLERE ST DENIS J & COMPANY LLC (8.93%), Villere ST Denis J & Co. LLC (9.31%), Vanguard Group Inc. (8.42%), RGM Capital LLC (6.63%) and Dimensional Fund Advisors LP (4.20%). Company insiders that own Luminex Corporation stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir and Russell W Bradley. View Institutional Ownership Trends for Luminex Corporation.

Luminex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Kalmar Investments Inc. DE, Acadian Asset Management LLC, Great Lakes Advisors LLC, American Century Companies Inc., Bank of Montreal Can, Wells Fargo & Company MN, Eos Focused Equity Management L.P. and Russell Investments Group Ltd.. Company insiders that have sold Luminex Corporation stock in the last year include G Walter Loewenbaum II and Kevin M Mcnamara. View Insider Buying and Selling for Luminex Corporation.

Luminex Corporation's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., RGM Capital LLC, Elk Creek Partners LLC, Renaissance Technologies LLC, Blair William & Co. IL, Vanguard Group Inc., State Street Corp and Neuberger Berman Group LLC. Company insiders that have bought Luminex Corporation stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex Corporation.

Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Luminex Corporation stock can currently be purchased for approximately $21.22.